Drug
Compound 2055269
Compound 2055269: highest development phase Phase 2, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| COMPOUND 2055269 NCT03503630 | Phase 2 | Locally Advanced Rectal Cancer |
Latest
No recent events.
Follow Compound 2055269 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.